NASDAQ: CGONCg Oncology Inc Stock
$28.50-1.52 (-5.06%)
Updated May 10, 2024
CGON Price
$28.50
Fair Value Price
N/A
Market Cap
$1.90B
52 Week Low
$28.20
52 Week High
$50.23
P/E
N/A
P/B
3.34x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
N/A
Beta
1.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CGON Overview
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CGON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CGON is good value based on its book value relative to its share price (3.34x), compared to the US Biotechnology industry average (5.91x)
P/B vs Industry Valuation
CGON's short-term assets ($578.61M) exceed its short-term liabilities ($9.98M)
Short-term Liabilities Financials
CGON's short-term assets ($578.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more CGON due diligence checks available for Premium users.
Be the first to know about important CGON news, forecast changes, insider trades & much more!
CGON News
Valuation
CGON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.34x
Industry
5.91x
CGON is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CGON's financial health
Profit margin
Revenue
$529.0k
Net Income
-$16.9M
Profit Margin
-3,200.8%
Assets to liabilities
Assets
$579.1M
Liabilities
$10.2M
Debt to equity
0.02
CGON's short-term assets ($578.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGON's short-term assets ($578.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.0M
Investing
-$307.4M
Financing
$402.7M
CGON vs Biotech Stocks
Cg Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.